Skip to main content
    C

    Cardinal Health Inc (CAH)

    Official site

    HEALTHCARE • MEDICAL DISTRIBUTION • NYSE

    $283.87
    +2.77 (+0.99%)

    Market Cap: $64.97B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Cardinal Health Inc (CAH) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Cardinal Health (CAH) is expected to report earnings on Feb 3, 2027. In the quarter ended Sep 30, 2026, Cardinal Health reported EPS of $3.26, above the $2.92 estimate. It beat the EPS estimate in each of the last 17 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    85%(34/40)
    Avg Surprise
    +10.45%
    Streak
    17 Q

    Upcoming Estimates

    Reports Feb 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$3.13
    Range$2.93 - $3.64
    10 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$3.07+1.9%
    60d ago$3.11+0.4%
    30d ago$3.12+0.1%
    7d ago$3.13-0.1%
    Current$3.13
    Revenue Consensus
    $68.36B
    Range$67.48B - $69.22B
    10 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$3.36
    Range$2.91 - $3.51
    10 analysts
    EPS Revisions
    2
    4
    30d
    EPS Estimate DriftChange to current
    90d ago$3.45-2.5%
    60d ago$3.37-0.2%
    30d ago$3.36+0.2%
    7d ago$3.36-0.0%
    Current$3.36
    Revenue Consensus
    $63.63B
    Range$61.92B - $64.34B
    10 analysts

    Next Report

    CAH has an expected report date of Feb 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 19.0% above the $2.63 reported for the quarter ended Dec 31, 2025.

    CAH Earnings Call

    The latest CAH earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, CAH beat 34 and missed 6. Revenue for the quarter ended Sep 30, 2026 was $67.51B, up 5.5% from $64.01B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$3.26$2.92$2.88 - $3.06+11.64%Beat+27.8%134 up, 3 downNov 5, 2026$67.51B
    Jun 30, 2026$2.91$2.42N/A+20.25%Beat+39.9%153 up, 0 downAug 11, 2026$63.67B
    Mar 31, 2026$3.17$2.79$2.67 - $3.01+13.62%Beat+34.9%153 up, 1 downApr 30, 2026$60.94B
    Dec 31, 2025$2.63$2.37$2.31 - $2.46+10.97%Beat+36.3%119 up, 0 downFeb 5, 2026$65.63B
    Sep 30, 2025$2.55$2.17$2.10 - $2.42+17.51%Beat+35.6%14N/AOct 30, 2025$64.01B
    Jun 30, 2025$2.08$2.03N/A+2.46%Beat+13.0%1512 up, 0 downAug 12, 2025$60.16B
    Mar 31, 2025$2.35$2.15$1.93 - $2.22+9.30%Beat+13.0%13N/AMay 1, 2025$54.88B
    Dec 31, 2024$1.93$1.76$1.46 - $1.88+9.66%Beat+6.0%132 up, 1 downJan 30, 2025$55.26B
    Sep 30, 2024$1.88$1.62$1.54 - $1.76+16.05%Beat+8.7%151 up, 0 downNov 1, 2024$52.28B
    Jun 30, 2024$1.84$1.73$1.70 - $1.77+6.36%Beat+18.7%141 up, 0 downAug 14, 2024$59.87B
    Mar 31, 2024$2.08$1.95$1.89 - $2.02+6.67%Beat+19.5%140 up, 2 downMay 2, 2024$54.87B
    Dec 31, 2023$1.82$1.60$1.50 - $1.74+13.75%Beat+37.9%132 up, 0 downFeb 1, 2024$57.44B
    Sep 30, 2023$1.73$1.41$1.34 - $1.49+22.70%Beat+44.2%110 up, 2 downNov 3, 2023$54.65B
    Jun 30, 2023$1.55$1.48$1.46 - $1.54+4.73%Beat+47.6%131 up, 0 downAug 15, 2023$53.42B
    Mar 31, 2023$1.74$1.49$1.45 - $1.56+16.78%Beat+20.0%142 up, 0 downMay 4, 2023$50.49B
    Dec 31, 2022$1.32$1.14$1.06 - $1.21+15.79%Beat+3.9%112 up, 0 downFeb 2, 2023$51.47B
    Sep 30, 2022$1.20$0.97$0.89 - $1.04+23.71%Beat-7.0%110 up, 2 downNov 4, 2022$49.60B
    Jun 30, 2022$1.05$1.18$1.13 - $1.20-11.02%Miss+36.4%111 up, 0 downAug 11, 2022$47.06B
    Mar 31, 2022$1.45$1.53$1.42 - $1.64-5.23%Miss-5.2%121 up, 1 downMay 5, 2022$44.84B
    Dec 31, 2021$1.27$1.23$1.11 - $1.32+3.25%Beat-27.0%12N/AFeb 3, 2022$45.46B
    Sep 30, 2021$1.29$1.35$1.26 - $1.41-4.44%Miss-14.6%10N/ANov 9, 2021$43.97B
    Jun 30, 2021$0.77$1.20$1.13 - $1.22-35.83%Miss-26.0%12N/AAug 5, 2021$42.59B
    Mar 31, 2021$1.53$1.56$1.47 - $1.76-1.92%Miss-5.6%14N/AMay 6, 2021$39.27B
    Dec 31, 2020$1.74$1.45$1.40 - $1.49+20.00%Beat+14.5%15N/AFeb 5, 2021$41.54B
    Sep 30, 2020$1.51$1.14$1.09 - $1.16+32.46%Beat+18.9%16N/ANov 5, 2020$39.06B
    Jun 30, 2020$1.04$0.89$0.71 - $1.13+16.85%Beat-6.3%14N/AAug 6, 2020$36.69B
    Mar 31, 2020$1.62$1.45$1.16 - $1.55+11.72%Beat+1.9%14N/AMay 11, 2020$39.16B
    Dec 31, 2019$1.52$1.22$1.15 - $1.29+24.59%Beat+17.8%13N/AFeb 6, 2020$39.73B
    Sep 30, 2019$1.27$1.09$1.04 - $1.14+16.51%Beat-1.6%15N/ANov 7, 2019$37.34B
    Jun 30, 2019$1.11$0.94$0.87 - $0.99+18.09%Beat+9.9%15N/AAug 8, 2019$37.35B
    Mar 31, 2019$1.59$1.41$1.30 - $1.54+12.77%Beat+14.4%16N/AMay 9, 2019$35.23B
    Dec 31, 2018$1.29$1.09$1.01 - $1.15+18.35%Beat-14.6%15N/AFeb 7, 2019$37.74B
    Sep 30, 2018$1.29$1.07$1.01 - $1.20+20.56%Beat+18.3%16N/ANov 8, 2018$35.21B
    Jun 30, 2018$1.01$0.93$0.89 - $0.97+8.60%Beat-22.9%17N/AAug 6, 2018$35.35B
    Mar 31, 2018$1.39$1.51$1.45 - $1.57-7.95%Miss-9.2%17N/AMay 3, 2018$33.63B
    Dec 31, 2017$1.51$1.16$1.09 - $1.29+30.17%Beat+12.7%16N/AFeb 8, 2018$35.19B
    Sep 30, 2017$1.09$1.00$0.96 - $1.06+9.00%Beat-12.1%13N/ANov 6, 2017$32.64B
    Jun 30, 2017$1.31$1.24$1.22 - $1.26+5.65%Beat+14.9%17N/AAug 2, 2017$32.97B
    Mar 31, 2017$1.53$1.46N/A+4.79%Beat+7.0%N/AN/AMay 1, 2017$31.82B
    Dec 31, 2016$1.34$1.23N/A+8.94%Beat+3.1%N/AN/AFeb 7, 2017$33.15B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Jun 30, 2026 was $11.26, up 36.7% from the year before. It was $5.42 for the year ended Jun 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Jun 30, 2026$11.26+36.7%
    Jun 30, 2025$8.24+10.3%
    Jun 30, 2024$7.47+28.6%
    Jun 30, 2023$5.81+14.8%
    Jun 30, 2022$5.06-8.8%
    Jun 30, 2021$5.55+1.8%
    Jun 30, 2020$5.45+3.2%
    Jun 30, 2019$5.28+5.6%
    Jun 30, 2018$5.00-7.7%
    Jun 30, 2017$5.42N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,700 words across 17 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,70117
    2026Q2Jun 30, 202610,06318
    2026Q1Mar 31, 20267,37015
    2025Q4Dec 31, 20258,72117
    2025Q3Sep 30, 20258,60718
    2025Q2Jun 30, 202510,72316
    2025Q1Mar 31, 20253,2788
    2024Q4Dec 31, 202410,66816

    2026Q3 Earnings Call

    Opening remarks

    Matt Sims Vice President, Investor Relations Good morning, and welcome to Cardinal Health's Third Quarter Fiscal '26 Earnings Conference Call, and thank you for joining us. With me today are Cardinal Health's CEO, Jason Hollar; and our CFO, Aaron Alt. You can find this morning's earnings press release and investor presentation on the Investor Relations section of our website at ir.cardinalhealth.com. Since we will be making forward-looking statements today, let me remind you that the matters addressed in these statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statement slide at the beginning of our presentation for a description of these risks and uncertainties. Please note that during our discussion today, the comments will be on a non-GAAP basis, unless specifically called out as GAAP. GAAP to non-GAAP reconciliations for all relevant periods can be found in the supporting schedules attached to our press release. For the Q&A portion of today's call, we kindly ask that you limit questions to one per participant so that we can try and give everyone an opportunity. With that, I will now turn the call over to Jason.

    Jason Hollar Chief Executive Officer Thanks, Matt, and good morning, everyone. We are pleased to report another strong quarter for Cardinal Health, building on the momentum we displayed over the past few years. This quarter's performance highlights the durability and resilience of our business and the team's disciplined execution. The results reinforce our conviction in the company's growth trajectory and ability to deliver long-term value creation. Our underlying operating strength continues to be led by our largest and most significant business Pharmaceutical and Specialty Solutions, and is amplified by contributions from our higher-margin growth businesses. Within Pharma, we delivered strong growth, highlighting the strength of our core. We continue to see benefits from our strategic focus on expanding our capabilities across Specialty, both downstream of providers and upstream with manufacturers. We are progressing the expansion of our MSO platforms, in particular with the Specialty Alliances multi-specialty offerings, delivering differentiated value to a growing network of physicians and enhancing patient care and access. The integration of Solaris into the Specialty Alliance remains on track, and we are taking actions to realize synergistic benefits across our portfolio. In GMPD, we continue to execute against our improvement plan. Our focus on simplification and cost optimization initiatives is producing tangible results, and we continue to see notable strength in our portfolio of Cardinal Health brand products. Our deliberate actions to simplify operations, enhance supply chain resiliency and drive commercial excellence remain strategic priorities as the business navigates the dynamic tariff environment.

    Frequently Asked Questions About CAH

    When is Cardinal Health's next earnings date?

    Cardinal Health's next earnings report is expected for Feb 3, 2027.

    Did CAH beat earnings estimates last quarter?

    Yes. Cardinal Health reported EPS of $3.26 for the quarter ended Sep 30, 2026, above the $2.92 estimate, a 11.64% surprise.

    What EPS do analysts expect from CAH next quarter?

    The consensus EPS estimate for Cardinal Health for the quarter ending Dec 31, 2026 is $3.13 from 10 analysts, with estimates from $2.93 to $3.64.

    How often does CAH beat earnings estimates?

    Cardinal Health beat the EPS estimate in each of the last 17 quarters, with an average surprise of +13.06%.